From the Blood Journals

From the Blood Journals

Research from the Blood family of journals: Blood and Blood Advances

Large Meta-Analysis Confirms Predictive Value of MRD Negativity in Myeloma

Achievement of measurable residual disease (MRD) negativity is associated with significant improvements in progression-free survival (PFS) and overall survival (OS) in patients with multiple...

Azacitidine Maintenance Fails to Improve Post-Transplant Outcomes in High-Risk AML and MDS

Maintenance treatment with single-agent azacitidine at a dose of 32 mg/m2 daily for five days did not lead to improved survival in patients with...

Registry Analysis Finds Patients With Hematologic Malignancies Are Highly Vulnerable to COVID-19

In an analysis of data from the first 250 patients enrolled in the ASH Research Collaborative (ASH RC) COVID-19 Registry for Hematology, researchers found...
WIB_icon

Discontinuing Eculizumab is Safe and Feasible in Patients With Atypical Hemolytic Uremic Syndrome

Discontinuation of anti-C5 agent eculizumab is feasible and safe in patients with atypical hemolytic uremic syndrome (aHUS), particularly in the 40% to 60% of...

Rethinking Autoimmune Neutropenia in Children

Authors of a registry analysis published in Blood Advances have identified two distinct autoimmune neutropenia entities in children who present with apparent primary autoimmune...
WIB_icon

Azacitidine and Romidepsin Combination Shows High Activity in Peripheral T-Cell Lymphoma

A combination regimen consisting of oral azacitidine and romidepsin was highly active in patients with peripheral T-cell lymphoma (PTCL), particularly in previously untreated patients...

Does Blood Group Affect Risk of Bleeding Events or Bleeding Severity?

According to research published in Blood Advances, people who experience bleeding of unknown causes are 48% more likely to have blood group O, compared...
WIB_icon

Machine Learning Detects Prognostic Associations Between Morphologic and Genetic Changes in MDS

A new artificial intelligence–based technique was able to establish correlations between genetic and morphologic biomarkers, revealing diagnostically and prognostically important relationships, according to results...
WIB_icon

Is Caplacizumab a Cost-Effective Strategy for Acquired TTP?

In February 2019, the FDA approved the anti–von Willebrand factor immunoglobulin fragment caplacizumab as the only agent specifically indicated for the treatment of adults...

Normal Results on D-Dimer Testing Can Safely Rule out Deep Vein Thrombosis

A simplified approach of an initial stand-alone D-dimer test followed by a single whole-leg compression ultrasound (CUS) in D-dimer positive patients can effectively and...
Advertisement

Current Issue

Mid-January 2021 Annual Meeting Edition

This issue features highlights from the 2020 ASH Annual Meeting, a look at doctor-patient gifting customs around the world, and more.

Block title